MedPath

Phase II study of perioperative mFOLFOX plus Panitumumab for stage III rectal cancer

Not Applicable
Recruiting
Conditions
rectal cancer
Registration Number
JPRN-UMIN000006039
Lead Sponsor
Yokohama City University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
43
Inclusion Criteria

Not provided

Exclusion Criteria

Previous treatment of rectal cancer Multiple cancer and/or double cancer Any severe concurrent medical condition which would make it undesirable

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath